2nd Edition

Antifungal Therapy, Second Edition

Edited By Mahmoud A. Ghannoum, John R. Perfect Copyright 2019
    536 Pages
    by CRC Press

    536 Pages 14 Color & 45 B/W Illustrations
    by CRC Press

    536 Pages 14 Color & 45 B/W Illustrations
    by CRC Press

    This new edition of Antifungal Therapy aims at providing concise, practical, need-to-know information for busy physicians dealing with fungal infections, such as infectious disease physicians, transplant surgeons, dermatologists, and intensivists, as well as basic scientists and pharmaceutical company researchers interested in the state of antifungal therapy. It provides a comprehensive, up-to-date overview of the pertinent issues pertaining to antifungal treatment including the basics of clinical mycology, management insights for various infections, evidence-based treatment recommendations, and helpful tables summarizing currently available pharmacokinetics data.

    Key Features

    • Features useful information on administration, dosage and pharmacology of antifungal drugs that can be difficult to use in clinical practice

    • Contains common Clinical Questions & Answers to highlight frequently encountered patient issues

    • Covers clinical mycology essentials in addition to antifungal treatment to create a well-rounded reference

    • Presents illustrations and clinical photos in full color to elucidate the concepts

    • Provides detailed evidence of treatment recommendations




    1. History of antifungals

    Emily L. Larkin, Ali Abdul Lattif Ali, and Kim Swindell

    2. Epidemiology of fungal infections: What, where, and when

    Frederic Lamoth, Sylvia F. Costa, and Barbara D. Alexander

    3. Experimental animal models of invasive fungal infections

    Christopher L. Hager, Lisa Long, Yoshifumi Imamura, and Mahmoud A. Ghannoum

    4. Antifungal drug resistance: Significance and mechanisms

    Sharvari Dharmaiah, Rania A. Sherif, and Pranab K. Mukherjee

    5. Antifungal prophylaxis: An ounce of prevention is worth a pound of cure

    Aimee K. Zaas

    6. Preemptive antifungal therapy: Do diagnostics help?

    Vidya Jagadeesan, Margaret Powers-Fletcher, and Kimberly E. Hanson

    7. The immune response to fungal challenge

    Jeffery Hu and Jeffery J. Auletta

    8. Immunomodulators: What is the evidence for use in mycoses?

    J. Andrew Alspaugh

    9. Fungal biofilms and catheter-associated infections

    Jyotsna Chandra and Mahmoud A. Ghannoum

    10. Polyenes for prevention and treatment of invasive fungal infections

    Richard H. Drew

    11. Flucytosine

    Richard H. Drew

    12. Pharmacology of azole antifungal agents

    Elizabeth S. Dodds Ashley

    13. Echinocandins for prevention and treatment of invasive fungal infections

    Melissa D. Johnson, John Mohr, and Ahmad Mourad

    14. Novel methods of antifungal administration

    Richard H. Drew

    15. Dermatophytosis

    Mahmoud A. Ghannoum, Iman Salem, and Nancy Isham

    16. Invasive candidiasis

    Richard R. Watkins and Tracy Lemonovich

    17. Invasive aspergillosis

    Frank Esper

    18. Management of cryptococcosis

    John R. Perfect and Ahmad Mourad

    19. Management of endemic mycoses

    John R. Perfect and Ahmad Mourad

    20. Human hyalohyphomycoses: A review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., Talaromyces spp., and Scopulariopsis spp.

    Nour Hasan

    21. Management of phaeohyphomycosis

    John R. Perfect and Ahmad Mourad

    22. Pneumocystis

    Kim Swindell

    23. Management of mucormycoses

    John R. Perfect and Ahmad Mourad

    24. Antifungal management in risk groups: Solid organ transplant recipients

    Jasmine Chung, Sylvia F. Costa, and Barbara D. Alexander

    25. Prophylaxis and treatment of invasive fungal infections in neutropenic cancer and hematopoietic cell transplant patients

    Daniel R. Richardson, Marcie L. Riches, and Hillard M. Lazarus

    26. Antifungal use in transplant recipients: Selection, administration, and monitoring

    Richard H. Drew, Mary L. Townsend, Melanie W. Pound, and Steven W. Johnson

    27. Infants: Yeasts are beasts in early life

    Rachel G. Greenberg and Daniel K. Benjamin Jr.

    28. Newer antifungal agents in pediatrics

    William J. Steinbach

    29. Fungal infections in burn patients

    Nour Hasan

    30. Allergic bronchopulmonary aspergillosis


    Mahmoud A. Ghannoum, PhD, MBA, FIDSA, FAAM joined Case Western Reserve University and University Hospitals Case Medical Center in 1996 from prior positions at the UCLA School of Medicine and Kuwait University. Dr. Ghannoum has spent his entire academic career studying medically important fungi encompassing different fungal pathogens including Candida, Aspergillus, and Cryptococcus, the major causes of fungal infections. He has published more than 350 peer-reviewed articles addressing various aspects of superficial and systemic fungal infections. More recently, he published the first study describing the oral mycobiome of healthy individuals. He has published extensively in the area of fungal pathogenesis with special focus on virulence factors including phospholipase B, germination, adhesion, and biofilm formation, both in vitro and in vivo. Dr. Ghannoum is a professor and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Case Medical Center. This center of excellence, which he directs, is a multidisciplinary center that combines basic and translational research investigating fungi from the test tube to the bedside. He has performed several studies investigating the mechanisms underlying Candida pathogenesis. He is the recipient of the Freedom to Discover Award from Bristol- Myers Squibb and the Rhoda Benham Award from the Medical Mycological Society of the Americas. He served as a chairman of the Subcommittee on Antifungal Susceptibility Testing, Clinical Laboratory Standards Institute, and was selected as a "Most Interesting Person" by Cleveland Magazine in 2013. Dr. Ghannoum is an entrepreneur-scientist who has launched a number of companies focusing on the treatment of biofilm infections and microbial dysbiosis as it relates to gut health. He coined the term ‘Mycobiome’.

    John R. Perfect, MD, is James B. Duke Professor of Medicine at Duke University Medical Center, a faculty member of the Duke University Interdisciplinary Program in Genetics, and director of the Duke University Mycology Research Unit. He is chief of the Division of Infectious Diseases in the Department of Medicine at Duke Medical Center. Dr. Perfect is a diplomat of the American Board of Internal Medicine and American Board of Infectious Diseases. After receiving an undergraduate degree in biology from Wittenberg University, Dr. Perfect went on to receive a medical degree from the Medical College of Ohio at Toledo. He then completed an internship at the Riverside Methodist Hospital in Columbus, Ohio; a residency in internal medicine at the University of Michigan Medical Center in Ann Arbor; and a fellowship in infectious diseases at Duke University Medical Center. He is a fellow of the American Society for Microbiology and the Infectious Diseases Society of America. Dr. Perfect is also a fellow of the American Association for Advancement of Science and member of International Society for Human and Animal Mycology, and Immunocompromised Host Society (ISHAM). He is president of the Mycoses Study Group and Educational Research Consortium and president-elect of ISHAM. Dr. Perfect has served on numerous committees and advisory boards. He received the Rhoda Benham Award from Medical Mycology Society of the Americas and the Lucille Georg Award from ISHAM. Dr. Perfect’s research interests focus on the understanding of fungal pathogenesis through the study of Cryptococcus neoformans as well as clinical studies on the epidemiology, diagnosis, and management of invasive mycoses.

    "This book succeeds overall as an important reference and a comprehensive review of the current state of antifungal therapy in humans. The up-to-date information makes it a useful resource for clinicians consulting for immunosuppressed patients with invasive mycoses. The scientific data presented and the clinical experience and insight of the expert authors on the use of newer antifungal drugs in the pediatric population in the last section will be
    particularly useful in guiding practicing pediatricians in the care of their patients. Perhaps the last chapter is one of the most valuable of all, putting in perspective the mycobiome, which, as a part of the microbiome, plays a key role in health and disease."

    Robert Gene Penn, MD (Nebraska Methodist Hospital)